Crofelemer Placebo Powder for Oral Solution
Sponsors
Napo Therapeutics S.p.A., Napo Pharmaceuticals Inc.
Conditions
Microvillous Inclusion Disease (MVID)Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon-in-continuity (CIC
Phase 2
Evaluation of Safety, Tolerability and Efficacy of Crofelemer following Multiple Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Participants with Microvillus Inclusion Disease (MVID)
RecruitingCTIS2024-512845-18-00
Start: 2025-06-03Target: 4Updated: 2025-05-23
A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of adult patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon in continuity (CIC)
RecruitingCTIS2024-511994-31-00
Start: 2025-03-10Target: 22Updated: 2025-12-23